Plaque modification in calcified chronic total occlusions: the PLACCTON study.

INTRODUCTION AND OBJECTIVES: Severe calcification is present in> 50% of coronary chronic total occlusions (CTOs) undergoing percutaneous intervention. We aimed to describe the contemporary use and outcomes of plaque modification devices (PMDs) in this context. METHODS: Patients were included in the prospective, consecutive Iberian CTO registry (32 centers in Spain and Portugal), from 2015 to 2020. Comparison was performed according to the use of PMDs. RESULTS: Among 2235 patients, wire crossing was achieved in 1900 patients and PMDs were used in 134 patients (7%), requiring more than 1 PMD in 24 patients (1%). The selected PMDs were rotational atherectomy (35.1%), lithotripsy (5.2%), laser (11.2%), cutting/scoring balloons (27.6%), OPN balloons (2.9%), or a combination of PMDs (18%). PMDs were used in older patients, with greater cardiovascular burden, and higher Syntax and J-CTO scores. This greater complexity was associated with longer procedural time but similar total stent length (52 vs 57mm; P=.105). If the wire crossed, the procedural success rate was 87.2% but increased to 96.3% when PMDs were used (P=.001). Conversely, PMDs were not associated with a higher rate of procedural complications (3.7 vs 3.2%; P=.615). Despite the worse baseline profile, at 2 years of follow-up there were no differences in the survival rate (PMDs: 94.3% vs no-PMDs: 94.3%, respectively; P=.967). CONCLUSIONS: Following successful wire crossing in CTOs, PMDs were used in 7% of the lesions with an increased success rate. Mid-term outcomes were comparable despite their worse baseline profile, suggesting that broader use of PMDs in this setting might have potential technical and prognostic benefits.

First-in-Man Evaluation of a Sirolimus-Eluting Stent With Abluminal Fluoropolymeric/Triflusal Coating With Ultrathin Struts by OCT at 9 Months' Follow-Up: The PROMETHEUS Study.

OBJECTIVES: We sought to investigate stent healing and neointimal hyperplasia with ihtDEStiny drug-eluting stent (DES) by optical coherence tomography (OCT) examination conducted 9 months after implantation. BACKGROUND: The currently used DES present certain features that have been linked separately to their better performance in terms of efficacy and safety. METHODS: First-in-man, prospective and multicenter study including patients treated with ihtDEStiny stent undergoing OCT examination at 9 months follow up. The ihtDEStiny stent is a sirolimus eluting stent with an oval shape ultrathin struts (68 µm) and an abluminal coating of a fluoropolymer containing the antiplatelet agent triflusal. Primary endpoint was the percentage of obstruction of the in-stent volume by the neointima. RESULTS: In 58 patients (63 lesions) in-stent late lumen loss was 0.11 ± 0.23 mm (95% CI 0.05-0.16) with only in 6% of stents being > 0.5 mm and in-segment binary stenosis was 1.6%. In OCT mean neointima volume obstruction was 10.5 ± 6.9% with a mean neointima thickness of 110.9 ± 89.8 µm. The proportion of uncovered struts was 2.5%, malapposed struts 1.1% and malapposed/uncovered struts 0.7% and no subclinical thrombi detected. Mean incomplete stent apposition area was 0.1 ± 0.1 mm2. At 12 months target lesion revascularization rate was 3% and no stent thrombosis was reported. CONCLUSIONS: In this study the ihtDEStiny stent has shown a very low degree of neointimal proliferation associated with a low rate of uncovered/malapposed struts and total absence of subclinical thrombi at 9 months follow up.

Clinical Outcomes After Implantation of Polyurethane-Covered Cobalt-Chromium Stents: Insights from the Papyrus-Spain Registry.

BACKGROUND/PURPOSE: The main indication of covered stents (CS) is coronary artery perforation (CAP), but, they have been increasingly used in other scenarios. Data on the long-term follow-up of CS is limited, and no studies have been conducted specifically using new-generation polyurethane-covered cobalt-chromium Papyrus CS. PURPOSE: to evaluate the clinical outcomes after hospital discharge of Papyrus CS and to compare their outcome after implantation in CAP or coronary artery aneurysms (CAA). METHODS/MATERIALS: We evaluated the baseline clinical characteristics, lesion subsets, procedural features and the outcomes after initial discharge of Papyrus CS implanted in 17 high-PCI-volume centers. RESULTS: 127 Papyrus CS were implanted in 108 patients (68 ±â€¯1 years; 82.8% male) admitted for stable coronary disease (32.3%), NSTEMI (42.4%) or STEMI (25.3%). The number of CS per patient was 1.2 ±â€¯0.6 (diameter: 3.5 ±â€¯1.7 mm; length: 18.5 ±â€¯3.7 mm). Angiographic success rate was 96%. CS diameter was larger in CAA (CAP:3.04 ±â€¯0.5 mm vs CAA:4.1 ±â€¯2.7 mm; p = .022). Intracoronary imaging techniques were used more frequently in CAA (p < .0001). After a mean follow-up of 22 ±â€¯16 months, the major cardiovascular adverse events (MACE) rate was 7.1% [cardiac death: 2%, Myocardial infarction: 5%, Target Lesion Revascularization: 5% and Stent Thrombosis (ST): 3%]. MACE rate was similar in CAP (7.7%) and CAA (7.1%) (p = .9). However, CAA showed a higher ST rate (CAP: 0% vs CA: 7.1%; p = .04). CONCLUSION: After hospital discharge, clinical outcomes after Papyrus CS implantation are acceptable (considering the clinical scenario and compared with other treatment alternatives) with no significant differences in the MACE rate between those implanted in CAA or in CAP. However, CAA group showed a higher ST rate.

The Pt-Cr everolimus-eluting stent with bioabsorbable polymer in the treatment of patients with acute coronary syndromes. Results from the SYNERGY ACS registry.

OBJECTIVES: We investigated the safety and efficacy of the bioabsorbable polymer-coated, everolimus-eluting coronary stent (SYNERGY) stent in a real-world study population with acute coronary syndromes (ACS). BACKGROUND: A number of clinical trials support the overall efficacy and safety of the SYNERGY stent. However, a recent trial (TIDES-ACS) in the context of ACS reported worrying figures of infarction and definite/probable stent thrombosis in the SYNERGY control arm. METHODS: This is a multicenter registry (10 centers) including consecutive patients with ACS (unstable angina, non-ST elevated myocardial infarction, ST elevated myocardial infarction) who underwent percutaneous revascularization with the implantation of SYNERGY stent. The primary endpoint was the composite of cardiac death, myocardial infarction and target lesion revascularization at 12 months. RESULTS: A total of 1008 patients were included with age 65.4 ±â€¯14.8 years, 23.8% females and a 24.5% diabetics. Regarding presentation, a 15.2% with unstable angina, 43% with non-ST elevated myocardial infarction and 41.8% with ST elevated myocardial infarction. Primary outcome was met in 3% (7% in SYNERGY TIDES-ACS arm, P superiority <0.01 and 6.3% in OPTIMAX TIDES-ACS arm, P superiority <0.01). Cardiac death was 1.3% (1.6%, p = 0.8 and 0.5%, P superiority =0.1 respectively). Myocardial infarction was 1.6% (4.6%, p < 0.01 and 1.8%, P superiority = 0.9 respectively). Target lesion revascularization was 1% (3.4%, p < 0.01 and 5.4%, P superiority <0.01 respectively). Definite or probable thrombosis was 0.9% (2.8%, p ≤ 0.01 and 1.1%, P superiority = 0.8 respectively). CONCLUSIONS: The results of this registry show a very good safety and efficacy profile at 12 months for the SYNERGY stent in patients with ACS. SUMMARY: A recent trial (TIDES-ACS) in the context of acute coronary syndromes (ACS) reported worrying figures of infarction and definite/probable stent thrombosis in the SYNERGY stent control arm. We investigated the safety of SYNERGY stent in a real-world study population with ACS applying the same inclusion/exclusion criteria as used in the TIDES-ACS trial. Primary endpoint was the composite of cardiac death, myocardial infarction and TLR at 12 months. A total of 1008 patients have been included. Primary outcome was met in 3% (7% in SYNERGY TIDES-ACS arm, P superiority <0.01 and 6.3% in OPTIMAX TIDES-ACS arm, P superiority <0.01).

STEMI with fluctuating closing of LAD and Cx: Do not concentrate on the finger.

Case report of the male with an anterior STEMI to whom a primary PCI is performed. The angiogram shows a fluctuating close of the LAD and Cx than when an OCT is performed does not clearly see any pathological findings but when the IVUS is performed, it is clearly seen as a coronary haematoma at the LM, LAD and Cx. Stent at the LM-LAD and proximal Cx are implanted with final good result. After exchanging the guiding catheter for a diagnostic catheter to visualize the RCA, there is an aortic flap; the coronary haematoma was coming from an ascending aortic dissection. The CT confirms the type A aortic dissection and the patient is sent to urgent surgery where it seems that the point of intimal disruption is close to brachiocephalic trunk; a supracommissural ascending aortic replacement is performed. After several complications the patient did well and he is alive. Although the patient got the right approach, as we focused on the coronary arteries we did not realized there was an aortic dissection until the end of the procedure.

Percutaneous intervention in chronic total coronary occlusions caused by in-stent restenosis: procedural results and long-term clinical outcomes in the TORO (Spanish registry of chronic TOtal occlusion secondary to an occlusive in-stent RestenOsis) multicentre registry.

AIMS: Limited data exist on the treatment and outcomes of patients with chronic total occlusions due to in-stent restenosis (CTO-ISR). We sought to evaluate results and clinical outcomes in percutaneous interventions over CTO-ISR. METHODS AND RESULTS: We conducted a registry in 16 centres involving consecutive patients undergoing attempted percutaneous intervention over CTO-ISR. A total of 233 patients were included, 192 (82.4%) with a successful acute result. The success rate was significantly lower in patients with: lesion in the circumflex artery, ostial lesions, J score >3 and no femoral access. The presence of tandem lesions (OR 0.19, 95% CI: 0.06-0.68; p=0.01) was identified as an independent predictor for outcome. After a median follow-up of 20 months, cardiac death in the successful vs. failed groups was 3% and 8.3%, respectively (p=0.09). Independent predictors for mortality were previous CABG (HR 8, 95% CI: 1.3-50; p=0.02) and multivessel disease (HR 2.3, 95% CI: 1.2-4.3; p=0.01). In the successful group, TLR was 15%, re-occlusion 6% and definite/probable stent thrombosis 1.8%. CONCLUSIONS: Percutaneous treatment of CTO due to ISR in contemporary practice shows a high success rate, resulting in good long-term results. The angiographic and procedural predictors identified may contribute to improving procedural outcome through better patient selection.

[Transseptal catheterization using electrophysiological landmarks in ablation procedures]. / Punción transeptal mediante referencias electrofisiológicas para procedimientos de ablación.

Since the development of radiofrequency catheter ablation for the treatment of atrial fibrillation, electrophysiology laboratories have experienced a significant rise in the number of transseptal catheterization procedures. Traditionally, the procedure requires the presence of a interventional cardiologist who carries out transseptal catheterization following arterial puncture and placement of a reference pigtail catheter in the aortic root. Use of His bundle and coronary sinus catheters to provide anatomical and electrophysiological landmarks enables transseptal catheterization to be carried out without the need for arterial puncture or intracavity pressure measurement. We report our experience with transseptal catheterization in an electrophysiology laboratory using only electrophysiological landmarks. The procedure was carried out on 68 occasions and was successful in all patients except one, in whom catheterization could not be performed for anatomical reasons and because the patient had previously received anticoagulation therapy. One other patient developed transient ST elevation, which was probably due to an air embolism.

Punción transeptal mediante referencias electrofisiológicas para procedimientos de ablación / Transseptal catheterization using electrophysiological landmarks in ablation procedures

Desde el desarrollo de la ablación con radiofrecuencia para el tratamiento curativo de la fibrilación auricular, los laboratorios de electrofisiología han experimentado un incremento considerable en el número de cateterismos transeptales. Tradicionalmente, el procedimiento requería la intervención de un hemodinamista que procedía a realizar el cateterismo transeptal previa punción arterial y colocación de un catéter pigtail de referencia en la raíz aórtica. Utilizando el catéter del His y el del seno coronario como referencias anatomo-electrofisiológicas se puede llevar a cabo el cateterismo transeptal sin necesidad de realizar punción arterial ni medición de presiones intracavitarias. Presentamos nuestra experiencia en cateterización transeptal en el laboratorio de electrofisiología utilizando referencias puramente electrofisiológicas. Hemos realizado el procedimiento en 68 ocasiones, con resultado exitoso en todos los casos salvo en uno, en el que la punción no pudo llevarse a cabo por dificultades en el acceso anatómico y porque el paciente se encontraba previamente anticoagulado. Un paciente presentó elevación transitoria del segmento ST, probablemente debida a un embolismo aéreo

Since the development of radiofrequency catheter ablation for the treatment of atrial fibrillation, electrophysiology laboratories have experienced a significant rise in the number of transseptal catheterization procedures. Traditionally, the procedure requires the presence of a interventional cardiologist who carries out transseptal catheterization following arterial puncture and placement of a reference pigtail catheter in the aortic root. Use of His bundle and coronary sinus catheters to provide anatomical and electrophysiological landmarks enables transseptal catheterization to be carried out without the need for arterial puncture or intracavity pressure measurement. We report our experience with transseptal catheterization in an electrophysiology laboratory using only electrophysiological landmarks. The procedure was carried out on 68 occasions and was successful in all patients except one, in whom catheterization could not be performed for anatomical reasons and because the patient had previously received anticoagulation therapy. One other patient developed transient ST elevation, which was probably due to an air embolism

Angiomixoma agresivo de pelvis con afectación cardiaca / Aggressive angiomyxoma of the pelvis with cardiac involvement

No disponible

[Diagnosis of acute myocarditis by contrast-enhanced cardiac magnetic resonance imaging]. / Diagnóstico de miocarditis aguda por cardiorresonancia magnética con contraste.

Myocarditis is defined as an inflammatory process of the heart muscle. The symptoms are often nonspecific, and it can mimic acute coronary syndrome. Although the majority of patients recover fully, in some cases myocarditis can lead to dilated cardiomyopathy and even death. Available diagnostic tools are unsatisfactory and there is a need to develop noninvasive techniques that can aid diagnosis, prognosis, and follow-up. Contrast-enhanced magnetic resonance imaging is a valuable tool for the evaluation of inflammatory heart diseases such as myocarditis. We describe a 39-year-old man presenting in the emergency department with chest pain, ST segment elevation and elevated cardiac enzymes, who was treated initially with thrombolysis. Coronary angiography showed normal coronary arteries. Magnetic resonance imaging showed focally delayed uptake of gadolinium with a patchy pattern typical of myocarditis.

Diagnóstico de miocarditis aguda por cardiorresonancia magnética con contraste / Diagnosis of acute myocarditis by contrast-enhanced cardiac magnetic resonance imaging

La miocarditis es un proceso inflamatorio del músculo cardíaco. Los síntomas suelen ser inespecíficos y pueden simular un síndrome coronario agudo. Si bien la mayoría de los pacientes presentan una recuperación completa, en ocasiones puede desarrollarse una miocardiopatía dilatada e incluso la muerte. Las técnicas diagnósticas disponibles no son satisfactorias y es necesario desarrollar técnicas no invasivas que puedan garantizar un diagnóstico, pronóstico y seguimiento. La resonancia magnética con realce tardío de contraste es una herramienta útil para la valoración de un proceso inflamatorio cardíaco como la miocarditis. Presentamos el caso de un varón de 39 años con dolor torácico, elevación del segmento ST e incremento de marcadores de daño miocárdico tratado inicialmente con trombólisis. La coronariografía mostró unas arterias coronarias angiográficamente normales. El estudio con resonancia magnética mostró captación focal tardía de gadolinio con patrón parcheado típico de miocarditis

Myocarditis is defined as an inflammatory process of the heart muscle. The symptoms are often nonspecific, and it can mimic acute coronary syndrome. Although the majority of patients recover fully, in some cases myocarditis can lead to dilated cardiomyopathy and even death. Available diagnostic tools are unsatisfactory and there is a need to develop noninvasive techniques that can aid diagnosis, prognosis, and follow-up. Contrast-enhanced magnetic resonance imaging is a valuable tool for the evaluation of inflammatory heart diseases such as myocarditis. We describe a 39-year-old man presenting in the emergency department with chest pain, ST segment elevation and elevated cardiac enzymes, who was treated initially with thrombolysis. Coronary angiography showed normal coronary arteries. Magnetic resonance imaging showed focally delayed uptake of gadolinium with a patchy pattern typical of myocarditis